Schizoaffective Disorder clinical trials

Explore recruiting schizoaffective disorder clinical trials.

Recruiting schizoaffective disorder studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Schizoaffective Disorder trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Long-term outcomes and safety of repeated rituximab treatment in psychotic disorders – RITS-LONG

Sweden

Therapeutic exploratory (Phase II) EU CTIS Study details

A randomised, controlled trial to investigate the effect of a six-week intensified pharmacological treatment for schizophrenia compared to treatment as usual in subjects who had a first-time treatment failure on their first-line treatment.

Austria, Germany, Spain, Italy

Therapeutic use (Phase IV) EU CTIS Study details

Ketamine for the treatment of depressive and negative symptoms in patients with schizophrenia: a randomized controlled cross-over pilot study.

Austria

Therapeutic confirmatory (Phase III) EU CTIS Study details

Single-arm, open-label dose titration phase 2 clinical trial of (+)-α-DHTBZ for the treatment of tardive dyskinesia (TD)

Croatia

Therapeutic exploratory (Phase II) EU CTIS Study details

A randomised, controlled trial to investigate the effect of a four/six week intensified pharmacological treatment for schizophrenia, major depressive disorder and bipolar depression compared to treatment as usual in subjects who had a first-time treatment failure on their first-line treatment.

Germany, Italy, Austria, Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

A prospective, randomized, and controlled study comparing two treatment strategies (Dose REduction of Antipsychotics vs. Maintenance treatment) in patients with schizophrenia spectrum disorder after Stratification based on patients’ psychotic PHENotype: a personalized medicine approach

France

Therapeutic confirmatory (Phase III) EU CTIS Study details

Schizoaffective Disorder trials by city

Schizoaffective Disorder in Toronto Schizoaffective Disorder in Vancouver Schizoaffective Disorder in Montreal Schizoaffective Disorder in Calgary Schizoaffective Disorder in Edmonton Schizoaffective Disorder in Ottawa Schizoaffective Disorder in Winnipeg Schizoaffective Disorder in Quebec City Schizoaffective Disorder in Hamilton Schizoaffective Disorder in Kitchener Schizoaffective Disorder in London Schizoaffective Disorder in Halifax Schizoaffective Disorder in New York Schizoaffective Disorder in Los Angeles Schizoaffective Disorder in Chicago Schizoaffective Disorder in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease